Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Buenos Aires; ANMAT; mar. 20, 2020.
Non-conventional in Spanish | LILACS | ID: biblio-1116469

ABSTRACT

En el marco de la actual situación de emergencia sanitaria, la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), establece las siguientes medidas y recomendaciones con el objeto de preservar las actividades de los estudios de farmacología clínica (EFC) protegiendo la seguridad y bienestar de los participantes del estudio. Los patrocinadores de los EFC deberán confeccionar un plan de mitigación de riesgo para extremar las medidas tendientes a evitar el contagio y diseminación de COVID-19 así como la saturación del sistema sanitario del país. Este plan deberá quedar debidamente documentado en el archivo de cada estudio y será notificado a los investigadores, centros de investigación, comités de Ética y a la ANMAT. Su aplicación no requiere aprobación previa como modificación sustancial por esta Administración. Algunos estudios podrán requerir modificaciones particulares que no se encuentren reflejadas en el plan de mitigación. Estas deberán ser consensuadas con el equipo de investigación y plasmarse en un documento. Este plan deberá ser presentado por cada patrocinador por única vez ante la ANMAT en un trámite caratulado como "comunicación a DERM" por la plataforma de trámites a distancia (TAD) y esta Administración Nacional tomará conocimiento del mismo. No será necesario esperar a una respuesta de esta Administración para su implementación.


Subject(s)
Pharmacology, Clinical/methods , Pharmacology, Clinical/standards , Pneumonia, Viral/drug therapy , Clinical Protocols/standards , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Argentina/epidemiology
2.
Braz J Med Biol Res ; 49(12): e5646, 2016 Dec 12.
Article in English | MEDLINE | ID: mdl-27982281

ABSTRACT

The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/No-Go decision, a drug candidate needs to pass through several steps, such as determination of drug availability (studies on pharmacokinetics), absorption, distribution, metabolism and elimination (ADME) and preliminary studies that aim to investigate the candidate safety including genotoxicity, mutagenicity, safety pharmacology and general toxicology. These preliminary studies generally do not need to comply with GLP regulations. These studies aim at investigating the drug safety to obtain the first information about its tolerability in different systems that are relevant for further decisions. There are, however, other studies that should be performed according to GLP standards and are mandatory for the safe exposure to humans, such as repeated dose toxicity, genotoxicity and safety pharmacology. These studies must be conducted before the Investigational New Drug (IND) application. The package of non-clinical studies should cover all information needed for the safe transposition of drugs from animals to humans, generally based on the non-observed adverse effect level (NOAEL) obtained from general toxicity studies. After IND approval, other GLP experiments for the evaluation of chronic toxicity, reproductive and developmental toxicity, carcinogenicity and genotoxicity, are carried out during the clinical phase of development. However, the necessity of performing such studies depends on the new drug clinical application purpose.


Subject(s)
Biomedical Research/standards , Drug Evaluation, Preclinical/standards , Laboratories/standards , Animals , Clinical Trials, Phase I as Topic , Drugs, Investigational/chemistry , Drugs, Investigational/pharmacokinetics , Humans , Mutagenicity Tests , Pharmacology, Clinical/standards
3.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;49(12): e5646, 2016. tab, graf
Article in English | LILACS | ID: biblio-828175

ABSTRACT

The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/No-Go decision, a drug candidate needs to pass through several steps, such as determination of drug availability (studies on pharmacokinetics), absorption, distribution, metabolism and elimination (ADME) and preliminary studies that aim to investigate the candidate safety including genotoxicity, mutagenicity, safety pharmacology and general toxicology. These preliminary studies generally do not need to comply with GLP regulations. These studies aim at investigating the drug safety to obtain the first information about its tolerability in different systems that are relevant for further decisions. There are, however, other studies that should be performed according to GLP standards and are mandatory for the safe exposure to humans, such as repeated dose toxicity, genotoxicity and safety pharmacology. These studies must be conducted before the Investigational New Drug (IND) application. The package of non-clinical studies should cover all information needed for the safe transposition of drugs from animals to humans, generally based on the non-observed adverse effect level (NOAEL) obtained from general toxicity studies. After IND approval, other GLP experiments for the evaluation of chronic toxicity, reproductive and developmental toxicity, carcinogenicity and genotoxicity, are carried out during the clinical phase of development. However, the necessity of performing such studies depends on the new drug clinical application purpose.


Subject(s)
Humans , Animals , Biomedical Research/standards , Drug Evaluation, Preclinical/standards , Laboratories/standards , Clinical Trials, Phase I as Topic , Drugs, Investigational/chemistry , Drugs, Investigational/pharmacokinetics , Mutagenicity Tests , Pharmacology, Clinical/standards
4.
São Paulo; Associação Paulista para o Desenvolvimento da Medicina; 3 ed; 2013. 247 p. ilus, tab.
Monography in Portuguese | LILACS, Coleciona SUS, Sec. Est. Saúde SP | ID: lil-699562
5.
Invest. educ. enferm ; 28(2): 163-170, jul. 2010.
Article in English, Spanish | LILACS, BDENF - Nursing | ID: lil-560484

ABSTRACT

Objetivo. Describir las labores de prescripción de medicamentos que realizaron los profesionales de enfermería en la ciudad deCali (Colombia) durante el año 2008. Metodología. Se realizó una encuesta a 135 enfermeras que laboran en diferentes tipos de servicios asistenciales o administrativos sobre hábitos de formulación, percepciones sobre su formación, capacidades y necesidades para ejercer la prescripción de medicamentos. Resultados. La prescripción de medicamentos es una práctica frecuente en la mayoría de la población encuestada, sin relación con el trabajo que desempeñan, la formación de postgrado o la experiencia laboral. Para ejercer esta labor, los encuestados consideran que necesitan formación en farmacología más que un respaldo legal; sin embargo, no reconocen esta actividad como parte de las funciones de su profesión. La prescripción de medicamentos por enfermeras se presenta en algunos casos como una función de la institución donde laboran. Conclusión. La prescripción de medicamentos es una práctica que se ejerce entre los enfermeros de la ciudad, y de acuerdo con los resultados presentados, requiere un debate académico, legal y gremial para ser considerada entre el que hacer de la profesión.


Objective. To describe the drug prescription duties held by nursing professionals in the city of Cali (Colombia) during the year of 2008. Methodology. A survey was applied to 135 nurses who work in different kinds of healthcare or administrative services about prescription habits, perceptions about their education, abilities and necessities to prescribe drugs. Results. Drug prescription is a frequent practice in most of the surveyed population, unrealeted to the work performed, the postgraduate degree or the job experience. The surveyed consider they need more than a legal support the pharmacological training to prescribe drugs; however they don’t recognize this practice as part of their professional job. Nurses’ drug prescription is sometimes presented as part of their occupation tasks into the institution. Conclusion. Drug prescription is a practice performed by the city nurses and according to the presented results they require an academic, legal, professional debate to be considered between their tasks.


Objetivo. Descrever os labores de prescrição de medicamentos que realizaram os profissionais de enfermgem na cidade de Cali (Colômbia) durante o ano 2008. Metodologia. Realizou-se uma enquete a 135 enfermeirasque laboram em diferentes tipos de serviços assistenciais ou administrativos sobre hábitos de formulação, percepções sobre sua formação, capacidades e necessidades para exercer a prescrição de medicamentos. Resultados. A prescrição de medicamentos é uma prática frequente na maioria da população interrogada, sem relação com o trabalho que desempenham, a formação de pós-graduação ou a experiência trabalhista. Para exercer este labor, os interrogados consideram que precisam formação em farmacologia mais do que um respaldo legal; no entanto, não reconhecem esta atividade como parte das funções de sua profissão. A prescrição de medicamentos por enfermeiras se apresenta em alguns casos como uma função da instituição onde laboram. Conclusão. a prescrição de medicamentos é uma prática que se exerce entre os enfermeiros da cidade, e de acordo com os resultados apresentados, requer um debate acadêmico, legal e do grêmio para ser considerada entre o afazer da profissão.


Subject(s)
Pharmacology, Clinical/standards , Pharmacology, Clinical/ethics , Drug Prescriptions , Education, Nursing , Nursing Research
6.
Prensa méd. argent ; Prensa méd. argent;95(2): 111-114, abr. 2008.
Article in Spanish | LILACS | ID: lil-497663

ABSTRACT

Las reacciones adversas a medicamentos representan entre el 5 y 10 por ciento de las internaciones y son la quinta o sexta causa de muerte en países desarrollados. La farmacovigilancia es una herramienta fundamental para disminuir la morbimortalidad producida por drogas... Las drogas son causa frecuente de prolongación de internación así como también de aumento de la morbimortalidad en pacientes hospitalizados.


Subject(s)
Humans , Pharmacology, Clinical/standards , Health Surveillance , Adverse Drug Reaction Reporting Systems/statistics & numerical data
7.
Rev. méd. Minas Gerais ; 9(1): 25-8, jan.-mar. 1999. tab, graf
Article in Portuguese | LILACS | ID: lil-247695

ABSTRACT

A terapia apropriada para o paciente geriátrico deve ser ponto de especial atençäo na prática clínica diária. Muitas alteraçöes nas funçöes normais do corpo derivadas do processo de envelhecimento precisam ser ponderadas antes da introduçäo de qualquer terapia. Para se determinar boa prescriçäo é necessário dedicar atençäo especial a certas variaçöes que surgem com o envelhecimento, como, reduçäo das reservas fisiológicas normais; alteraçöes na absorçäo, distribuiçäo e eliminaçäo das drogas; alteraçäo na sensibilidade dos diversos tecidos aos fármacos; diminuiçäo da capacidade do sistema imunológico e deficiência protéica ou hábito de tabagismo e seus efeitos pelos anos de uso.


Subject(s)
Humans , Aged/physiology , Aging/drug effects , Pharmacology, Clinical/standards , Geriatrics/standards
11.
Corrientes; Universidad Nacional del Nordeste;Facultad de Medicina; 1996. 153 p. tab.
Monography in Spanish | BINACIS | ID: biblio-1193473

ABSTRACT

Contenido: Psicofarmacología.- Farmacología de las Benzodiacepinas y la transmisión Gabaérgica, de las drogas antidepresivas, Clínica y de las sales de litio.- Neurolépticos antipsicóticos o tranquilizantes mayores.- Drogas anticonvulsivantes o antiepilépticas.- Antiparkinsonianos.- Fármacos que pueden causar síntomas psiquiátricos.- Farmacodependencia drogadicción.- Enfermedad de Alzheimer.- Utilización de fármacos en enfermedades hepáticas e insuficiencia renal.- Formas farmacéuticas.- Farmacovigilancia y mecanismos de reacciones adversas a medicamentos.- Cólera


Subject(s)
Humans , Antidepressive Agents , Benzodiazepines , Cholera/drug therapy , Chemical and Drug Induced Liver Injury/etiology , Alzheimer Disease/drug therapy , Pharmacology , Pharmacology, Clinical/methods , Psychotropic Drugs/adverse effects , Kidney , Anti-Anxiety Agents , Anticonvulsants , Antidepressive Agents, Tricyclic , Antidepressive Agents, Second-Generation , Antiparkinson Agents , Antipsychotic Agents , Lithium Carbonate , Cyclosporine , Lithium Compounds , Chemical and Drug Induced Liver Injury/diagnosis , Alzheimer Disease/diagnosis , Alzheimer Disease/physiopathology , Pharmacology, Clinical/standards , Renal Insufficiency, Chronic , Substance-Related Disorders , Homeopathic Vehicles , Product Surveillance, Postmarketing
12.
Corrientes; Universidad Nacional del Nordeste;Facultad de Medicina; 1996. 153 p. Tab. (66996).
Monography in Spanish | BINACIS | ID: bin-66996

ABSTRACT

Contenido: Psicofarmacología.- Farmacología de las Benzodiacepinas y la transmisión Gabaérgica, de las drogas antidepresivas, Clínica y de las sales de litio.- Neurolépticos antipsicóticos o tranquilizantes mayores.- Drogas anticonvulsivantes o antiepilépticas.- Antiparkinsonianos.- Fármacos que pueden causar síntomas psiquiátricos.- Farmacodependencia drogadicción.- Enfermedad de Alzheimer.- Utilización de fármacos en enfermedades hepáticas e insuficiencia renal.- Formas farmacéuticas.- Farmacovigilancia y mecanismos de reacciones adversas a medicamentos.- Cólera


Subject(s)
Humans , Benzodiazepines , Antidepressive Agents , Psychotropic Drugs/adverse effects , Pharmacology , Pharmacology, Clinical/methods , Alzheimer Disease/drug therapy , Chemical and Drug Induced Liver Injury/etiology , Kidney , Cholera/drug therapy , Antiparkinson Agents , Antidepressive Agents, Second-Generation , Antidepressive Agents, Tricyclic , Anticonvulsants , Substance-Related Disorders , Alzheimer Disease/diagnosis , Alzheimer Disease/physiopathology , Chemical and Drug Induced Liver Injury/diagnosis , Renal Insufficiency, Chronic , Cyclosporine , Pharmacology, Clinical/standards , Product Surveillance, Postmarketing , Homeopathic Vehicles , Lithium Compounds , Lithium Carbonate
13.
In. Wannmacher, Lenita; Ferreira, Maria Beatriz Cardoso. Farmacologia clínica para dentistas. Rio de Janeiro, Guanabara Koogan, 1995. p.182-93, ilus. (BR).
Monography in Portuguese | LILACS, BBO - Dentistry | ID: lil-168225
16.
Basel; Karger; 2 ed., rev; 1992. 570 p. ilus, tab, 26cm.
Monography in English | Sec. Est. Saúde SP, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1234745
17.
Folha méd ; 98(6): 415-20, 1989.
Article in Portuguese | LILACS | ID: lil-172246

ABSTRACT

Os ensaios clínicos sao técnicas científicas de avaliaçao da segurança e da eficácia dos medicamentos. O vasto número de diferentes entidades terapêuticas e a sua proporcional participaçao (20 a 30 por cento) no número de artigos publicados tornam mandatário o conhecimento clínico sobre os aspectos básicos envolvidos com estes processos, mormente considerando-se que a atitude terapêutica é a atividade-fim da Medicina.


Subject(s)
Clinical Trials as Topic , Pharmacology, Clinical/standards
SELECTION OF CITATIONS
SEARCH DETAIL